간질 임상시험 현황 : 동향과 분석(2026년판)

Epilepsy clinical research is increasingly focused on addressing drug-resistant epilepsy, rare genetic epilepsies, pediatric epilepsy syndromes, and novel therapeutic modalities that improve seizure control while enhancing patient quality of life.

Epilepsy is one of the most common chronic neurological disorders, affecting millions of people worldwide and characterized by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. Although numerous anti-seizure medications are available, nearly one-third of patients continue to experience uncontrolled seizures despite treatment, highlighting the need for innovative therapeutic options. Clinical trial landscape analysis provides comprehensive insights into ongoing and completed clinical studies, investigational therapies, sponsor activities, development phases, regulatory progress, study designs, and future commercialization opportunities.

Market Drivers

Rising Burden of Drug-Resistant Epilepsy

Approximately one-third of epilepsy patients do not achieve adequate seizure control with currently available anti-seizure medications. This significant unmet medical need is driving increased investment in clinical trials evaluating innovative pharmacological therapies, gene therapies, neuromodulation technologies, and precision medicine approaches.

Growing Focus on Rare Genetic Epilepsies

Advances in molecular diagnostics and genetic testing have improved identification of rare epilepsy syndromes such as Dravet syndrome, Lennox-Gastaut syndrome, and other developmental epileptic encephalopathies. Pharmaceutical companies are increasingly developing targeted therapies designed to address the underlying genetic mechanisms of these disorders.

Increasing Investment in Precision Medicine

The integration of genomic sequencing, biomarkers, advanced neuroimaging, artificial intelligence, and digital monitoring technologies is enabling more personalized epilepsy treatment and improving patient selection for clinical trials.

Expansion of Pediatric Clinical Research

Growing recognition of the long-term neurological impact of childhood epilepsy has increased investment in pediatric clinical trials evaluating safer and more effective therapies for infants, children, and adolescents with severe epilepsy syndromes.

Market Restraints

Complex Disease Heterogeneity

Epilepsy encompasses numerous seizure types, syndromes, and underlying causes, making patient stratification, endpoint selection, and clinical trial design increasingly complex.

Recruitment Challenges

Clinical trials often face recruitment difficulties due to strict eligibility criteria, competition among ongoing studies, and the relatively low prevalence of certain rare epilepsy syndromes.

Long-Term Safety Requirements

Since epilepsy frequently requires lifelong treatment, regulatory authorities require extensive long-term safety and efficacy data before approving new therapies, increasing development timelines and costs.

Clinical Trial and Technology Insights

The global epilepsy clinical trials landscape can be segmented by clinical development phase, indication, therapeutic modality, sponsor type, study design, and geography.

By clinical development phase, the landscape includes preclinical, Phase I, Phase II, Phase III, and Phase IV studies. Early-stage programs continue to evaluate novel therapeutic targets, while late-stage studies focus on confirming efficacy, safety, and long-term outcomes across broader patient populations.

By indication, clinical trials target focal epilepsy, generalized epilepsy, drug-resistant epilepsy, pediatric epilepsy syndromes, rare genetic epilepsies, developmental epileptic encephalopathies, and status epilepticus. Drug-resistant epilepsy remains one of the most active areas of research because of the significant unmet clinical need.

By therapeutic modality, investigational approaches include small-molecule anti-seizure medications, biologics, gene therapies, RNA-based therapies, cell therapies, neuromodulation devices, precision medicine approaches, and combination therapies.

By sponsor type, studies are conducted by pharmaceutical companies, biotechnology firms, academic institutions, government research organizations, contract research organizations (CROs), and international collaborative research networks.

Technological advances including artificial intelligence, wearable seizure monitoring devices, digital biomarkers, electroencephalography (EEG) analytics, decentralized clinical trials, real-world evidence, and genomic medicine continue to improve patient selection, endpoint assessment, and overall trial efficiency.

Clinical Development Trends

The epilepsy clinical research landscape continues to expand beyond conventional seizure control toward therapies capable of modifying disease biology and improving long-term neurological outcomes.

Key development trends include:

• Expansion of precision medicine programs for genetic epilepsies.
• Increasing investment in gene and RNA-based therapies.
• Greater emphasis on drug-resistant epilepsy.
• Growth of pediatric clinical development programs.
• Increased use of artificial intelligence and digital biomarkers.
• Adoption of decentralized and adaptive clinical trial designs.
• Expansion of neuromodulation and combination treatment strategies.

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations continue to accelerate innovation while expanding the global epilepsy clinical development pipeline.

Regional Insights

North America remains the leading region for epilepsy clinical research due to advanced neuroscience research infrastructure, substantial pharmaceutical investment, strong regulatory support, and high participation in multinational clinical trials.

Europe continues to play a major role through collaborative academic research networks, established epilepsy treatment centers, and favorable regulatory frameworks supporting neurological innovation.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to expanding healthcare infrastructure, improving diagnostic capabilities, increasing biotechnology investment, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening neurological research capabilities through healthcare modernization, improved access to specialist care, and increasing participation in global clinical development programs.

Competitive Landscape

The epilepsy clinical trials landscape includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and medical device developers.

Industry participants continue to invest in innovative anti-seizure therapies, precision medicine, gene therapy, neuromodulation technologies, biomarker-guided development, and artificial intelligence-assisted drug discovery. Strategic collaborations, licensing agreements, mergers and acquisitions, and research partnerships remain key strategies for accelerating pipeline development and commercialization.

Future Outlook

The future of epilepsy clinical research is expected to be driven by advances in precision medicine, gene therapy, RNA therapeutics, neurostimulation technologies, biomarker science, and artificial intelligence. Future clinical programs will increasingly focus on personalized treatment approaches, disease-modifying therapies, and interventions that improve both seizure control and long-term neurological function.

Growing integration of genomic profiling, wearable monitoring technologies, digital health platforms, and real-world evidence is expected to improve clinical trial efficiency while accelerating regulatory approvals and expanding access to innovative epilepsy therapies.

Conclusion

The global Epilepsy Clinical Trials Landscape, Developments, and Analysis market is expected to experience sustained growth through 2035, supported by increasing investment in neuroscience research, expanding development of next-generation anti-seizure therapies, advances in precision medicine, and growing focus on drug-resistant and rare genetic epilepsies. Although challenges including disease heterogeneity, lengthy clinical development, and patient recruitment remain, continued innovation in gene therapy, neuromodulation, artificial intelligence, and biomarker-guided treatment is expected to transform the future epilepsy treatment landscape.

Key Benefits of this Report

• Comprehensive analysis of the global epilepsy clinical trial landscape and ongoing research activities.
• Detailed evaluation of investigational therapies, clinical development phases, and pipeline trends.
• Competitive assessment of sponsors, strategic collaborations, and innovation initiatives.
• Insights into regulatory developments, emerging technologies, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, CROs, researchers, investors, healthcare providers, and policymakers.

What Businesses Use Our Reports For

Clinical pipeline monitoring, competitive intelligence, trial benchmarking, licensing evaluation, partnership identification, portfolio planning, investment analysis, regulatory strategy development, and commercialization planning.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive assessment of the global epilepsy clinical trial landscape by clinical development phase, indication, therapeutic modality, sponsor type, study design, and geography
• Analysis of ongoing, completed, recruiting, active, terminated, and planned clinical studies
• Evaluation of investigational therapies, clinical endpoints, patient recruitment trends, regulatory developments, and innovation strategies
• Competitive intelligence covering sponsor activities, strategic collaborations, licensing agreements, mergers and acquisitions, and pipeline benchmarking
• Future outlook on precision medicine, gene therapies, neuromodulation technologies, digital health, and commercialization opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Clinical Trials Landscape Overview
  • 1.1.1 Global Epilepsy Clinical Development Snapshot
  • 1.1.2 Active Trial Activity Trends
  • 1.1.3 Pipeline Maturity Assessment
  • 1.1.4 Innovation and Development Trends
  • 1.1.5 Future Clinical Development Outlook
• 1.2 Executive Clinical Intelligence
  • 1.2.1 Most Advanced Clinical Programs
  • 1.2.2 Key Trial Readouts and Milestones
  • 1.2.3 Emerging Therapeutic Modalities
  • 1.2.4 Sponsor Activity Assessment
  • 1.2.5 Regulatory and Commercial Outlook
• 1.3 Key Strategic Conclusions
  • 1.3.1 Clinical Development Opportunities
  • 1.3.2 Pipeline Risk Assessment
  • 1.3.3 Competitive Positioning Outlook

2. Pipeline Overview

• 2.1 Global Epilepsy Clinical Development Landscape
  • 2.1.1 Historical Evolution of Epilepsy Clinical Research
  • 2.1.2 Current Clinical Trial Inventory
  • 2.1.3 Active Sponsor Participation
  • 2.1.4 Trial Initiation Trends
  • 2.1.5 Pipeline Expansion Trends
• 2.2 Pipeline Composition Analysis
  • 2.2.1 Assets by Development Phase
  • 2.2.2 Assets by Mechanism of Action
  • 2.2.3 Assets by Modality
  • 2.2.4 Assets by Indication
  • 2.2.5 Assets by Sponsor Type
• 2.3 Historical Progression Trends
  • 2.3.1 Phase Advancement Trends
  • 2.3.2 Historical Approval Trends
  • 2.3.3 Clinical Success Rate Trends
  • 2.3.4 Attrition Rate Trends
  • 2.3.5 Development Timeline Trends

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Focal Epilepsy
  • 3.1.2 Generalized Epilepsy
  • 3.1.3 Drug-Resistant Epilepsy
  • 3.1.4 Pediatric Epilepsy Syndromes
  • 3.1.5 Rare Genetic Epilepsies
• 3.2 Epidemiology and Disease Burden
  • 3.2.1 Global Incidence Analysis
  • 3.2.2 Global Prevalence Analysis
  • 3.2.3 Age-Specific Disease Burden
  • 3.2.4 Mortality and Morbidity Assessment
  • 3.2.5 Economic Burden Assessment
• 3.3 Current Treatment Landscape
  • 3.3.1 Standard Anti-Seizure Medication Landscape
  • 3.3.2 Combination Therapy Utilization
  • 3.3.3 Device-Based Therapies
  • 3.3.4 Surgical Intervention Landscape
  • 3.3.5 Treatment Pathway Assessment
• 3.4 Unmet Clinical Needs
  • 3.4.1 Refractory Seizure Management
  • 3.4.2 Pediatric Treatment Challenges
  • 3.4.3 Rare Epilepsy Syndrome Treatment Gaps
  • 3.4.4 Long-Term Safety Challenges
  • 3.4.5 Precision Medicine Opportunities

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Sodium Channel Modulators
  • 4.1.2 GABAergic Therapies
  • 4.1.3 SV2A Modulators
  • 4.1.4 Glutamate Pathway Modulators
  • 4.1.5 Potassium Channel Modulators
  • 4.1.6 Neuroinflammation Targets
  • 4.1.7 Genetic and Molecular Targets
  • 4.1.8 Novel Mechanistic Approaches
• 4.2 Innovation Assessment
  • 4.2.1 First-in-Class Clinical Candidates
  • 4.2.2 Best-in-Class Clinical Candidates
  • 4.2.3 Precision Medicine Programs
  • 4.2.4 Disease-Modifying Approaches
  • 4.2.5 Next-Generation Therapeutic Strategies
• 4.3 Modality Analysis
  • 4.3.1 Small Molecule Therapies
  • 4.3.2 Biologic Therapies
  • 4.3.3 RNA-Based Therapies
  • 4.3.4 Gene Therapies
  • 4.3.5 Cell-Based Therapies

5. Clinical Development Intelligence

• 5.1 Global Clinical Trial Landscape
  • 5.1.1 Registered Trial Inventory Analysis
  • 5.1.2 Active Recruiting Studies
  • 5.1.3 Completed Studies Analysis
  • 5.1.4 Terminated and Withdrawn Studies Analysis
  • 5.1.5 Planned Clinical Development Programs
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Benchmarking
  • 5.2.2 Primary Endpoint Analysis
  • 5.2.3 Secondary Endpoint Analysis
  • 5.2.4 Trial Duration Benchmarking
  • 5.2.5 Comparator Selection Benchmarking
• 5.3 Patient Population Analysis
  • 5.3.1 Adult Epilepsy Trials
  • 5.3.2 Pediatric Epilepsy Trials
  • 5.3.3 Drug-Resistant Epilepsy Trials
  • 5.3.4 Rare Epilepsy Syndrome Trials
  • 5.3.5 Genetic Epilepsy Trials
• 5.4 Recruitment and Enrollment Intelligence
  • 5.4.1 Enrollment Rate Analysis
  • 5.4.2 Recruitment Timeline Benchmarking
  • 5.4.3 Site Activation Trends
  • 5.4.4 Geographic Enrollment Patterns
  • 5.4.5 Recruitment Challenges and Mitigation Strategies
• 5.5 Clinical Outcomes Intelligence
  • 5.5.1 Efficacy Endpoint Achievement Rates
  • 5.5.2 Safety and Tolerability Trends
  • 5.5.3 Trial Completion Rates
  • 5.5.4 Dropout Trend Analysis
  • 5.5.5 Clinical Success Drivers

6. Pipeline Segmentation Analysis

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Pipeline
    • 6.1.1.1 Asset Count and Distribution
    • 6.1.1.2 Molecule-Level Profiles
    • 6.1.1.3 Developer Company Analysis
    • 6.1.1.4 Mechanism Distribution
    • 6.1.1.5 Development Progression Trends
  • 6.1.2 Phase I Pipeline
    • 6.1.2.1 Asset Count and Distribution
    • 6.1.2.2 Molecule-Level Profiles
    • 6.1.2.3 Early Clinical Trial Assessment
    • 6.1.2.4 Safety Benchmarking
    • 6.1.2.5 Advancement Probability
  • 6.1.3 Phase II Pipeline
    • 6.1.3.1 Asset Count and Distribution
    • 6.1.3.2 Molecule-Level Profiles
    • 6.1.3.3 Proof-of-Concept Assessment
    • 6.1.3.4 Mid-Stage Trial Benchmarking
    • 6.1.3.5 Advancement Probability
  • 6.1.4 Phase III Pipeline
    • 6.1.4.1 Asset Count and Distribution
    • 6.1.4.2 Molecule-Level Profiles
    • 6.1.4.3 Registrational Trial Assessment
    • 6.1.4.4 Regulatory Readiness Analysis
    • 6.1.4.5 Approval Probability
  • 6.1.5 Filed / Under Review Assets
    • 6.1.5.1 Asset Count and Distribution
    • 6.1.5.2 Regulatory Status Assessment
    • 6.1.5.3 Approval Timeline Forecasting
    • 6.1.5.4 Commercial Launch Readiness
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Ion Channel Modulators
  • 6.2.2 GABAergic Therapies
  • 6.2.3 SV2A Modulators
  • 6.2.4 Genetic and RNA Therapies
  • 6.2.5 Novel Mechanism-Based Therapies
• 6.3 Pipeline by Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 RNA Therapies
  • 6.3.4 Gene Therapies
  • 6.3.5 Cell Therapies
• 6.4 Pipeline by Indication
  • 6.4.1 Focal Epilepsy
  • 6.4.2 Generalized Epilepsy
  • 6.4.3 Drug-Resistant Epilepsy
  • 6.4.4 Pediatric Epileptic Encephalopathies
  • 6.4.5 Rare Genetic Epilepsy Syndromes

7. Probability of Success and Risk Analysis

• 7.1 Clinical Phase Transition Modeling
  • 7.1.1 Preclinical-to-Phase I Transition Probability
  • 7.1.2 Phase I-to-Phase II Transition Probability
  • 7.1.3 Phase II-to-Phase III Transition Probability
  • 7.1.4 Phase III-to-Approval Transition Probability
  • 7.1.5 Overall Approval Probability Assessment
• 7.2 Risk-Adjusted Pipeline Assessment
  • 7.2.1 Asset-Level Risk Scoring
  • 7.2.2 Clinical Development Risk Assessment
  • 7.2.3 Regulatory Risk Assessment
  • 7.2.4 Commercial Risk Assessment
  • 7.2.5 Competitive Risk Assessment
• 7.3 Attrition Analysis
  • 7.3.1 Attrition by Clinical Phase
  • 7.3.2 Attrition by Mechanism of Action
  • 7.3.3 Attrition by Modality
  • 7.3.4 Attrition by Indication
  • 7.3.5 Root Cause Failure Analysis
• 7.4 Probability-Weighted Commercial Opportunity
  • 7.4.1 Risk-Adjusted Revenue Potential
  • 7.4.2 Asset-Level Commercial Forecasting
  • 7.4.3 Peak Sales Potential Assessment
  • 7.4.4 Scenario-Based Forecast Modeling

8. Launch Timeline and Commercial Potential

• 8.1 Regulatory Milestone Forecasting
  • 8.1.1 Expected Submission Timelines
  • 8.1.2 Expected Approval Timelines
  • 8.1.3 Launch Sequence Analysis
  • 8.1.4 Competitive Entry Timing Assessment
• 8.2 Commercial Opportunity Assessment
  • 8.2.1 Addressable Patient Population
  • 8.2.2 Eligible Treatment Population
  • 8.2.3 Market Penetration Potential
  • 8.2.4 Peak Sales Potential
• 8.3 Future Market Evolution
  • 8.3.1 Standard-of-Care Evolution
  • 8.3.2 Precision Medicine Adoption Trends
  • 8.3.3 Rare Disease Commercial Opportunities
  • 8.3.4 Long-Term Market Outlook

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Pipeline Strength Analysis
  • 9.1.1 Leading Epilepsy Developers
  • 9.1.2 Emerging Biotech Innovators
  • 9.1.3 Rare Disease Specialists
  • 9.1.4 Academic and Institutional Sponsors
• 9.2 Competitive Benchmarking
  • 9.2.1 Pipeline Breadth Comparison
  • 9.2.2 Pipeline Depth Comparison
  • 9.2.3 Innovation Leadership Assessment
  • 9.2.4 Clinical Development Leadership Assessment
• 9.3 Asset Concentration Analysis
  • 9.3.1 Leading Assets by Clinical Advancement
  • 9.3.2 Leading Assets by Commercial Potential
  • 9.3.3 High-Risk High-Reward Programs
  • 9.3.4 White Space Opportunities
• 9.4 Sponsor Strategy Assessment
  • 9.4.1 Development Strategy Benchmarking
  • 9.4.2 Partnership and Collaboration Strategies
  • 9.4.3 Rare Disease Focus Assessment
  • 9.4.4 Competitive Positioning Analysis

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Speed
  • 10.1.3 Innovation Hubs
  • 10.1.4 Sponsor Activity
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Speed
  • 10.2.3 Innovation Hubs
  • 10.2.4 Sponsor Activity
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Speed
  • 10.3.3 Innovation Hubs
  • 10.3.4 Sponsor Activity
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Speed
  • 10.4.3 Innovation Hubs
  • 10.4.4 Sponsor Activity
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Speed
  • 10.5.3 Innovation Hubs
  • 10.5.4 Sponsor Activity

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timeline Assessment
  • 11.1.3 Key Sponsors
  • 11.1.4 Innovation Ecosystem
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Activity
  • 12.1.1 Pipeline Asset Licensing Trends
  • 12.1.2 Regional Licensing Activity
  • 12.1.3 Mechanism-Specific Licensing Trends
• 12.2 Strategic Collaborations
  • 12.2.1 Co-Development Agreements
  • 12.2.2 Clinical Research Collaborations
  • 12.2.3 Commercialization Partnerships
• 12.3 Mergers and Acquisitions
  • 12.3.1 Pipeline Asset Acquisitions
  • 12.3.2 Rare Disease Transactions
  • 12.3.3 Strategic Portfolio Expansion
• 12.4 Funding Landscape
  • 12.4.1 Venture Capital Funding Trends
  • 12.4.2 Private Equity Activity
  • 12.4.3 Public Market Financing
  • 12.4.4 Funding by Clinical Stage

13. Future Outlook and Strategic Insights

• 13.1 Future Clinical Development Outlook
  • 13.1.1 Precision Medicine Expansion
  • 13.1.2 Genetic Epilepsy Development Trends
  • 13.1.3 RNA Therapeutics Outlook
  • 13.1.4 Disease-Modifying Therapy Outlook
• 13.2 Strategic Opportunity Assessment
  • 13.2.1 Drug-Resistant Epilepsy Opportunities
  • 13.2.2 Pediatric Epilepsy Opportunities
  • 13.2.3 Rare Disease Opportunities
  • 13.2.4 Geographic Expansion Opportunities
• 13.3 Long-Term Competitive Outlook
  • 13.3.1 Future Market Leaders
  • 13.3.2 Competitive Landscape Evolution
  • 13.3.3 Commercial Opportunity Outlook

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Pipeline Identification Methodology
  • 14.1.2 Clinical Trial Validation Framework
  • 14.1.3 Forecasting Methodology
  • 14.1.4 Asset Verification Protocol
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Register
  • 14.2.3 Regulatory Filings
  • 14.2.4 Company Pipeline Disclosures
  • 14.2.5 Government Databases
  • 14.2.6 Peer-Reviewed Publications
• 14.3 Modeling Framework
  • 14.3.1 Probability of Success Modeling
  • 14.3.2 Risk Adjustment Methodology
  • 14.3.3 Revenue Forecast Methodology
  • 14.3.4 Commercial Opportunity Modeling
• 14.4 Validation and Limitations
  • 14.4.1 Data Quality Assessment
  • 14.4.2 Assumptions Framework
  • 14.4.3 Model Limitations
  • 14.4.4 Verification Protocol